{"name":"Ariad Pharmaceuticals","slug":"ariad-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":118804000,"revenueGrowth":12.7,"grossMargin":0,"rdSpend":171216000,"netIncome":-231156000,"cash":546692000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ponatinib - Phase 1","genericName":"ponatinib - Phase 1","slug":"ponatinib-phase-1","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ponatinib - Phase 1","genericName":"ponatinib - Phase 1","slug":"ponatinib-phase-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcURPSXg3ZFZuaThOR1g3bXhNenRqNUFGOW5ZZGtjcFJFNW00V1VPdXdLVTVweXRGLWRWdGw2VktKckk5YVBhZ0RuUkQyWk9iRi1LWV9TdlFXVzRwRU53ejFSMVBlMklFWDhQVjhDTm5kX2hQNHlJR2ZZbHcycGh3UkgwRXkzMVp6aUVxa01ZcUFqYnltVk1vTnpVTllCbnZxdUFPS09lN3lreGt3LWdhdTZMMWdmTUxtd0x4ZDZZa0s?oc=5","date":"2021-04-13","type":"pipeline","source":"Fierce Biotech","summary":"Theseus Pharmaceuticals emerges from stealth with $100M series B and Ariad veterans at the helm - Fierce Biotech","headline":"Theseus Pharmaceuticals emerges from stealth with $100M series B and Ariad veterans at the helm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxObWVjNWp6Znp1c3BiY1l0VjJBaGI4QXBuNFo3N0ttZjhMalVuWk1DNUQ0cVhscGxSV1hjTXZPellGR2l1eU5JZVpQdURSRk9qcm16MTVtTUowa09BTDJQVGJuRThtbW1LVHdwVFlvaHgtbnJmLXdBWmpiZFhqYzlLQjlKajRQNEktMWc0dzRVNElwa2VHU0xmOQ?oc=5","date":"2017-06-28","type":"pipeline","source":"BioPharma Dive","summary":"SEC charges ex-Ariad employees with insider trading - BioPharma Dive","headline":"SEC charges ex-Ariad employees with insider trading","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPckdDZnFLYUstdnFoaTNGRXp2UWl0T1ZkUnVlX1AzbGt4NVRUSlIyTlZvQTVEMEVZSHFzd0o0VFpWOUFNMHRFYkFYdXZUSE11MnhBVF8wUjh2aElYRXA5cXpuTUwwcVdDMkZVYnVZNW1FVWVfTl8zU3dwMlBiR0lNYW9jMWdPTFJXeDRMZ3p3RHpubjJnVlE1REVCSUs4UzFITXYtMFcxS3FQZmp5OV9LQ3lYNVNnd3c?oc=5","date":"2017-02-21","type":"pipeline","source":"Mynewsdesk","summary":"Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. - Mynewsdesk","headline":"Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.","sentiment":"neutral"},{"date":"2017-02-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOeFZSREtrYjNEbDREMC1JekhzcWszZEtsU3F5RU4tYmtjT3RLaGRNT3pCMWI2Mk9wNVJxVV9oZzJ3eE9nT3k5VzV0ZEp3bm81YzlLWjdScy1OT0huTm5UWmw5RktwS0h0TUI1NUJCeDA0bHp4NXo3cF9WT2xlYVd4NC15MVhyTktxM0VmWlVkNXFreE9DSEFhUFBKTzF2d0NJU2VuSHFsUmNaSUpVTlBzTWVDeS1OZkFYSmc?oc=5","date":"2017-01-09","type":"pipeline","source":"Fierce Pharma","summary":"Takeda shells out whopping $5.2B for Ariad, Iclusig and its fledgling med brigatinib - Fierce Pharma","headline":"Takeda shells out whopping $5.2B for Ariad, Iclusig and its fledgling med brigatinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOQ0gyc1ZqWXFodU5zNlpoWXJPQzFVUDRMenNCaWswb2pIbnFaLXNzTzBVU3dYeGJDd3UyRkdlSlJJLWtMcWdkel96Tko3ZzRXTzhqSDVTeWZXb1ZwNGZCWnRXNDVpQVVQOFl0WXRHRVVsNG15R3JobDNBM2JuY3J3ZmZFY0V4WEFsVUh4MW9hdTJ6U1lSM0NaS25DT0g4NGJKMF9HYTlRYmhkOW5xNUJzdUFaRzdadEs2TmE4SEVpMzBESXJPZ0E?oc=5","date":"2017-01-09","type":"pipeline","source":"Forbes","summary":"Ariad's $5.2 Billion Sale To Takeda Nets $260 Million Windfall For Hedge Fund - Forbes","headline":"Ariad's $5.2 Billion Sale To Takeda Nets $260 Million Windfall For Hedge Fund","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOcXVMQ01CbGx4bVIzWEFMeE5URGZfSEU5SWt2cmNkVkhBMGdIODFTQUFySXctVmY5SnBIUlBSdzBCM0JESVhQRnFZLUFKU25zbExxMVlIanE0czlSNjlBSGNFb2RSTFhQS3BTdWpLekttMEJRUVp0M1lKMEdNT1JfVjVjRDgtOFhiTTBHOHE1TUg1UQ?oc=5","date":"2017-01-09","type":"deal","source":"the-scientist.com","summary":"Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion - the-scientist.com","headline":"Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion - the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNSHpEZE02cUtCemUzdjhYN0VwaVpXZzUtcXk0bTZ1bXRVa3hjeFlaN1VVek0yLWRMV3N2N1N6ZWpuRmVpbllpa1dwalRYNEtKU0JjYjl0bDJ5TmhSQ2U4Tk12WW1WZl9FZm54aFVCYmxQdTFIbWNsZ0RsdDZaM3pOd2MxcEFqMFp5a0JIZmFJbjVyR0dHLUpyLXhlUmZ5U3BlcVVMbjFWQkJzQzU0V0hyc1gxRl9RVy13eHlZ?oc=5","date":"2017-01-09","type":"deal","source":"Reuters","summary":"Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal - Reuters","headline":"Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2016-10-20","type":"pipeline","source":"CNBC","summary":"Bernie Sanders requests info from Ariad Pharmaceuticals on its leukemia drug - CNBC","headline":"Bernie Sanders requests info from Ariad Pharmaceuticals on its leukemia drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNZHNaWGFCck8xWmtySE4yRWZVWDRCQnhfT2h4cGo3Tjc0QUZiU2tXaTRMejdtVzRUbG9RR2tFeG5CSTFpR1FUY3ZpeW9GNU15U0o2bHppeWx1M3dXRjFQTzRiZDI4OFBpZDNCUTBFbWxFRU50YnhkMExOVEVLckVQdW5CUDViTm8xYmRVMXFJTmZ1UWE0NWJqSlF1MUM5eHhRQWlVa3lNRmZQNGNKclBhdXZkMXdTMFZXc05LNGI3Uklld2tR?oc=5","date":"2016-10-13","type":"regulatory","source":"Healthcare Packaging","summary":"Ariad Pharma Uses Labeling Issue To Jack Up Price - Healthcare Packaging","headline":"Ariad Pharma Uses Labeling Issue To Jack Up Price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNcmw4X005WVlBZ2lOXzBlelRKU0hRYjBmekt0bFh2ZWtQR2g5aW9TMGgwZTh5bWRDQ1EzTEVVVFZRNXpPdVpnN3Z1WGFaaWowbWNHUEViWjBoR3ViQVlkRDB0Y3QzVE1CM0tLNzV2a3gtV3BqS3NJRm5scXZFMlRSSHpoSWM5MDdqN3lyRVhvcTdma2xLWlNIbnNoYWVjTkZoQWc?oc=5","date":"2015-04-17","type":"trial","source":"The Pharma Letter","summary":"Ariad announces updated Phase I/II results on brigatinib - The Pharma Letter","headline":"Ariad announces updated Phase I/II results on brigatinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQWFQ4eVNRZHlnUTZMRzY2LWZ4dEpiaDQ5amtaLXJpd0ExWTVSaGlybDFsT2VuQUxLNXA2WnBzZnNpajQweDNPR0VublBLb2ljUDBlSGdEeC1uU1NaLWpLYU1JdUN4ZGN3U3Fqd0RGWi0weEM1T2hJZzN6eEtCaTdDN1pMcXJ0OERPeWo3Ry1ud0ZORmhv?oc=5","date":"2015-01-05","type":"pipeline","source":"PMLiVE","summary":"Angelini to market Ariad’s Iclusig in Eastern Europe - PMLiVE","headline":"Angelini to market Ariad’s Iclusig in Eastern Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOcUxRLVVrbVJ1cl8xRngydGJHZDZYck9ENDVldmdoeGVkN0JQMVQ1bERRY3pGbFNuZVlPaFYyTHZWOHZXbklpQWRjQ3NfRXVUelVOREQ1Y0V5QlRRNHFFSUtQTkhOODVVV2o1UWdKSVI3TWpiZDZHYmpqTy0tZDFnNXVDLU45aGg5WUV5TkhlNUFrdmUtZ0FITDJPX194MlNNdUZCeHUxY0JtWE1mMXcybzdPTDRteklYLTU4ZjF0dFZ5SzRkMnNQQlB1NkRqcmtI?oc=5","date":"2011-04-05","type":"pipeline","source":"Buchanan Ingersoll & Rooney","summary":"Ariad v. Eli Lilly: The Federal Circuit Confirms A Written Description Requirement Exists, Separate from Enablement - Buchanan Ingersoll & Rooney","headline":"Ariad v. Eli Lilly: The Federal Circuit Confirms A Written Description Requirement Exists, Separate from Enablement - Bu","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":118804000,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":118804000,"period":"2015-12-31"},{"value":105412000,"period":"2014-12-31"},{"value":105412000,"period":"2014-12-31"},{"value":45561000,"period":"2013-12-31"},{"value":45561000,"period":"2013-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":171216000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-231156000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":546692000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}